Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBT: 2022-2025

Historic EBT for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$54.7 million.

  • Centessa Pharmaceuticals' EBT fell 30.43% to -$54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$239.3 million, marking a year-over-year decrease of 51.15%. This contributed to the annual value of -$232.9 million for FY2024, which is 32.23% down from last year.
  • Centessa Pharmaceuticals' EBT amounted to -$54.7 million in Q3 2025, which was down 10.41% from -$49.6 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' EBT's 5-year high stood at -$24.7 million during Q1 2025, with a 5-year trough of -$110.3 million in Q4 2024.
  • Its 3-year average for EBT is -$48.9 million, with a median of -$43.1 million in 2024.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' EBT plummeted by 208.97% in 2024, and later spiked by 34.15% in 2025.
  • Centessa Pharmaceuticals' EBT (Quarterly) stood at -$43.8 million in 2022, then rose by 18.58% to -$35.7 million in 2023, then plummeted by 208.97% to -$110.3 million in 2024, then slumped by 30.43% to -$54.7 million in 2025.
  • Its EBT was -$54.7 million in Q3 2025, compared to -$49.6 million in Q2 2025 and -$24.7 million in Q1 2025.